Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 4/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245716 | 0.98 | HDAC1 (0.51) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL23176838 | 0.98 | HDAC1 (0.51) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL3244845 | 0.94 | TAAR1 (0.52) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL67365 | 0.86 | TAAR1 (0.55) | HDAC1HDAC8TAAR1MAOBMIF | |
| SCHEMBL5539497 | 0.86 | PTPN2 (0.45) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5543455 | 0.84 | PTPN2 (0.44) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL11932723 | 0.81 | MAOB (0.58) | HDAC1HDAC8TAAR1FDFT1MAOB | |
| SCHEMBL5542719 | 0.81 | HDAC1 (0.53) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5540875 | 0.81 | HDAC1 (0.53) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5541663 | 0.80 | DAO (0.41) | HDAC1HDAC8DAOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861066-A | Deuterated maleic acid fluvoxamine and synthesis method thereof | 青岛职业技术学院 | 2021-12-31 | — | — | CN | claimed |
| EP-0881221-B1 | DIOXANE DERIVATIVES, LIQUID-CRYSTAL COMPOSITIONS CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY DEVICES MADE BY USING THE SAME | JNC CORP (JP) | 2016-06-29 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6235355-B1 | OPTICAL APPARATUS WITH LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0881221-A1 | DIOXANE DERIVATIVES, LIQUID-CRYSTAL COMPOSITIONS CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY DEVICES MADE BY USING THE SAME | CHISSO CORPORATION (JP) | 1998-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HDAC1 322/4885HDAC8 993/4885TAAR1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.